TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03383874

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probio-Tec BG-VCap-6.5
Description: The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo is made almost identically to the Probio-Tec but without active microorganisms.
Study: NCT00635960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone (Somatropin)
Description: The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as for Growth hormone group
Study: NCT00805103

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy
Description: Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
Study: NCT00300937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 100 mg oral BID starting at week 20 until delivery
Study: NCT01979016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background treatment
Description: Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background treatment
Description: Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
Study: NCT03715010

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA
Description: Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
Study: NCT03715010

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BCAA
Description: Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
Study: NCT00022139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01224067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine
Description: Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
Study: NCT04327557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCP Childbirth Education Course
Description: The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-MBCP Childbirth Education Course
Description: TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
Study: NCT00936585

Intervention type: OTHER
Group type: OTHER
Intervention: Immunologic Monitoring
Description: blood draws and colonoscopy before and after receiving study drug
Study: NCT03403465

Intervention type: OTHER
Group type: OTHER
Intervention: FDG PET scan
Description: At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
Study: NCT01491789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The VSail-Access simulator
Description: You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
Study: NCT00003191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Study: NCT05052814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal medicament-calcium hydroxide
Description: Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal medicament-chlorhexidine gel
Description: Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: root canal medicament-calcuim hyroxide &chlorhexidine ge
Description: Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
Study: NCT03905265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
Study: NCT02446236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV Day 1
Study: NCT02808208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)
Description: A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)
Description: A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Description: Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
Study: NCT04427072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: 400 mg, capmatinib tablets, administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 by intravenous infusion every 21 days
Study: NCT03213665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT02831959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200M device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard of Care
Study: NCT03565913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EffCaMgCit
Description: Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CaAcS
Description: CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
Study: NCT00500994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
Study: NCT02493803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Advice
Description: Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
Study: NCT04099472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium Education, Prevention, and Management
Description: Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
Study: NCT02344485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMM treatment
Description: OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
Study: NCT01521208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LUCAS (Lund University Cardiac Assist Sysrem)
Description: LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual chest compressions
Description: Manual CPR according to 2010 ERC guidelines will be performed
Study: NCT00203177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: 0.5 rasagiline mesylate
Study: NCT03277898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (Wait-list Control)
Description: Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
Study: NCT02447250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varied albuterol dose response
Description: Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
Study: NCT01265563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine placebo and silibin placebo
Description: Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine active and silibin placebo
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine placebo and silibin active
Description: Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine active and silibin active
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine active + high-dose silibin active
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
Study: NCT00620178

Intervention type: DRUG
Intervention: Candesartan Cilexetil
Description: oral once daily dose

Intervention type: DRUG
Intervention: Losartan
Description: once daily oral dose
Study: NCT01380197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nubain
Description: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).
Study: NCT02553200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BreatheMAX (OPEP)
Description: for 10 breathes/set, 10 sets/day and rest 1 minute between set

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX (OIS and OPEP)
Description: for 10 breathes/set, 10 sets/day and rest 1 minute between set

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BreatheMAX (unload and non-oscillated)
Description: for 10 breathes/set, 10 sets/day and rest 1 minute between set
Study: NCT01649674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycole (PEG) solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium picosulphate and magnesium citrate solution
Study: NCT01345968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject 50 mg/ml
Description: iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: iv administration of max. 50 ml in 30 minutes
Study: NCT00673205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 150mg p.o. daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04155918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
Description: AR882 + Febuxostat, AR882 alone, Febuxostat alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
Description: AR882 + Allopurinol, AR882 alone, Allopurinol alone
Study: NCT01184313

Intervention type: PROCEDURE
Intervention: aortic valve surgery with CPB
Description: elective aortic valve surgery with CPB
Study: NCT00960011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROGRIP
Description: Use of PROGRIP mesh for open inguinal hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POLYPROPYLENE
Description: Use of Polypropylene mesh in open inguinal hernia repair
Study: NCT02130687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
Study: NCT00203177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate 1.0 mg
Description: 1.0 mg rasagiline mesylate